Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Astrid Schulze"'
Autor:
Christel Weiss, Astrid Schulze, Shanshan Du, Job Harenberg, Christina Giese, Sandra Kraemer, Roland Kraemer
Publikováno v:
Seminars in Thrombosis and Hemostasis. 40:129-134
Dabigatran, rivaroxaban, and apixaban are direct oral anticoagulants (DOAC) inhibiting thrombin or factor Xa and effectively preventing thromboembolic complications using fixed doses without need for laboratory-guided dose adjustment. Plasma samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4b5d4f75374cfbc0bab13bb89d8e3d
https://doi.org/10.1055/s-0033-1363462
https://doi.org/10.1055/s-0033-1363462
Publikováno v:
Sportverletzung · Sportschaden. 27:156-161
Einleitung: Eine verminderte Dehnfahigkeit der ischiocruralen Muskulatur fuhrt zu einem erhohten Verletzungsrisiko. Ziel ist deshalb die Herstellung einer muskularen Balance. Der Active-Knee-Extension-Test (AKE) uberpruft die Dehnfahigkeit der ischio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4e798a1d3feb922009a8fb8994abcad
https://doi.org/10.1055/s-0033-1335783
https://doi.org/10.1055/s-0033-1335783
Autor:
Shanshan Du, Roland Krämer, Job Harenberg, Christel Weiss, Sandra Krämer, Astrid Schulze, Christina Giese
Publikováno v:
Seminars in Thrombosis and Hemostasis. 39:066-071
Rivaroxaban and dabigatran are new oral anticoagulants (NOACs) that inhibit directly factor Xa and thrombin, respectively. These NOACs effectively prevent thromboembolic complications using fixed doses without the need for dose adjustment according t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be443ea0aa25902caa7a741fc896f49
https://doi.org/10.1055/s-0032-1331155
https://doi.org/10.1055/s-0032-1331155
Autor:
Job Harenberg, Victor J. Marder, Martin Wehling, Svetlana Marx, Ola E. Dahl, Christel Weiss, Astrid Schulze
Publikováno v:
Thrombosis and Haemostasis. 108:903-912
SummaryNew oral anticoagulant (NOAC) regimens [dabigatran 150 mg (D150) and 220 mg (D220), rivaroxaban 10 mg (R20), and apixaban 2.5 mg bid (A5)] were effective and safe compared to enoxaparin for the prevention of venous thromboembolism (VTE) follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e1e4f2ea4958f25f85f421276575475
https://doi.org/10.1160/th12-07-0482
https://doi.org/10.1160/th12-07-0482
Autor:
Gregory Y.H. Lip, Shanshan Du, Sandra Krämer, Shabnam Zolfaghari, Job Harenberg, Martin Wehling, Christel Weiss, Roland Krämer, Astrid Schulze
Publikováno v:
European Journal of Clinical Investigation
Background The determination of rivaroxaban and apixaban from serum samples of patients may be beneficial in specific clinical situations when additional blood sampling for plasma and thus the determination of factor Xa activity is not feasible or re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460b054b1b2d10fcd24cbb5a94f47746
https://pubmed.ncbi.nlm.nih.gov/24931429
https://pubmed.ncbi.nlm.nih.gov/24931429
Publikováno v:
Volume 3: Design and Analysis.
The ambitious German energy program predicts a rapid expansion of regenerative power generation. Caused by the fluctuating nature of regenerative forms of energy, the need for backup capacities in the form of similar-sized thermal power plants is cle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32f6b5f2d1167212a03c22001548a608
https://doi.org/10.1115/pvp2012-78345
https://doi.org/10.1115/pvp2012-78345
Publikováno v:
Contact Dermatitis. 28:94-100
An animal model for the evaluation of skin protective creams against chemical irritants is described. The irritants were applied daily for 2 weeks to shaved back skin of young guinea pigs: sodium lauryl sulphate (5% aq.; 30 min), sodium hydroxide (0.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ded6248d8ff6a15681a146872e79594
https://doi.org/10.1111/j.1600-0536.1993.tb03350.x
https://doi.org/10.1111/j.1600-0536.1993.tb03350.x
Autor:
Karen Brøndum-Nielsen, Niels E. Skakkebæk, David H. Ledbetter, Claus Hansen, Astrid Schulze, Niels Tommerup
Publikováno v:
Nature Genetics. 12:452-454
The predominant genetic defects in Prader-Willi syndrome (PWS) are 15q11–q13 deletions of paternal origin and maternal chromosome 15 uni-parental disomy (UPD)1,2. In contrast, maternal deletions and paternal chromosome 15 UPD are associated with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f9bc014e25ea7960472e2f470d3a6d
https://doi.org/10.1038/ng0496-452
https://doi.org/10.1038/ng0496-452
Publikováno v:
European Journal of Medical Genetics. 52:271-272
Bergman et al. performed a search for exon copy number alterations in the CHD7 gene using MLPA in CHARGE syndrome patients who did not have a CHD7 mutation. Based on their results they recommended to extend testing using MLPA solely in individuals wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed6f89dfa1a39cb1b60578d134a3feab
https://doi.org/10.1016/j.ejmg.2009.02.005
https://doi.org/10.1016/j.ejmg.2009.02.005
Publikováno v:
Blood. 120:1162-1162
Abstract 1162 Rivaroxaban is approved at fixed dose for several indications to prevent thromboembolism. Despite the lack of need to dose adjust rivaroxaban it may be necessary to determine its activity/concentration in specific patient populations. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbff2ebb72a0745aa92b7c2ab5bb5270
https://doi.org/10.1182/blood.v120.21.1162.1162
https://doi.org/10.1182/blood.v120.21.1162.1162